NCT02022540View on ClinicalTrials.gov

Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD

PHASE1CompletedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

May 31, 2016

Conditions

Age-Related Macular Degeneration (AMD)

Interventions

DRUG

PAN-90806 Ophthalmic Solution

DRUG

Lucentis

Trial Locations (22)

Unknown

Colorado Springs

Winter Haven

Shawnee Mission

Wichita

Boston

Portsmouth

Bloomfield

Charlotte

Durham

Statesville

Ashland

Philadelphia

West Columbia

Rapid City

Nashville

Abilene

Austin

Harlingen

McAllen

San Antonio

Willow Park

Madison

Sponsors

Lead Sponsor

PanOptica, Inc.

All Listed Sponsors

lead

PanOptica, Inc.

INDUSTRY